CytoSorbents Corporation is a New Jersey-based critical care immunotherapy company specializing in developing products to aid in blood purification in order to control deadly inflammation in critically ill and cardiac surgery patients.
The company’s flagship product, CytoSorb®, is approved in the European Union with distribution in 43 countries around the world.
In 2020, RPR developed a campaign to help publicize Cytosorbents’ FDA Emergency Use Authorized blood purification medical device that can treat COVID-19 patients globally, in addition to sepsis, flu, trauma, burn injury, liver failure, and acute respiratory distress syndrome.
RPR secured coverage for CytoSorbents in FOX Business, Bloomberg, The Street, Yahoo Finance, TD Ameritrade Talks, and The Street, among many other publications.
Our earned media exposure for Cytosorbents helped the company reach their financing needs for their own research.